Mr. Levy is a serial entrepreneur and an experience manager specializing in establishing and managing technology companies in the areas of Targeted Protein Degradation drug discovery and cellular agriculture. Accept from his CEO roles he is co-founder and director of Sea2Cell Ltd – a cultivated fish startup and co-founder of Celleste Bio Ltd – a cultivated Cocoa startup. Between 2013 and 2019 he served as the General Manager of the Galilee Research Institute, a 300+ employees multidisciplinary applied research Institute. Before the Galilee research institute, he was the CEO of Proteologics Ltd, a publicly-traded drug discovery company that focused on drug discovery in the ubiquitin-proteasome pathway, and among its shareholders were Teva Pharmaceutical Industries (“Teva”) and Glaxo Smith Kline (“GSK”). He was also co-facilitator and served as a board member in several ventures including Immpact Bio, which develops disruptive CAR-T therapies based on an invention by the co-inventor of CAR-T, and among its shareholders are J&J, Takeda Ventures, Orbimed, and Novartis Venture Fund. Mr. Levy’s academic record includes Executive LL.M from the Northwestern law school Chicago IL, an M.Sc. (Genetics), an LL.B degree from Tel Aviv University, and BSc, Agr. from the Hebrew University of Jerusalem.

Mr. Levy is a lecturer in the biotechnology program at the Robert H. Smith Faculty of Agriculture of the Hebrew University of Jerusalem.